- Home
- GPRK vs CERS Comparison
GPRK vs CERS Comparison
Compare GPRK & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- CERS
- Stock Information
- Founded
- GPRK 2002
- CERS 1991
- Country
- GPRK Colombia
- CERS United States
- Employees
- GPRK N/A
- CERS N/A
- Industry
- GPRK Oil & Gas Production
- CERS EDP Services
- Sector
- GPRK Energy
- CERS Technology
- Exchange
- GPRK Nasdaq
- CERS Nasdaq
- Market Cap
- GPRK 324.3M
- CERS 347.3M
- IPO Year
- GPRK N/A
- CERS 1997
- Fundamental
- Price
- GPRK $6.54
- CERS $1.37
- Analyst Decision
- GPRK Buy
- CERS Strong Buy
- Analyst Count
- GPRK 1
- CERS 2
- Target Price
- GPRK $11.00
- CERS $3.50
- AVG Volume (30 Days)
- GPRK 895.9K
- CERS 1.3M
- Earning Date
- GPRK 05-14-2025
- CERS 05-01-2025
- Dividend Yield
- GPRK 9.01%
- CERS N/A
- EPS Growth
- GPRK N/A
- CERS N/A
- EPS
- GPRK 1.81
- CERS N/A
- Revenue
- GPRK $660,838,000.00
- CERS $180,270,000.00
- Revenue This Year
- GPRK N/A
- CERS $25.57
- Revenue Next Year
- GPRK $10.05
- CERS $10.54
- P/E Ratio
- GPRK $3.49
- CERS N/A
- Revenue Growth
- GPRK N/A
- CERS 15.29
- 52 Week Low
- GPRK $5.66
- CERS $1.12
- 52 Week High
- GPRK $11.72
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- GPRK 41.76
- CERS 48.70
- Support Level
- GPRK $6.26
- CERS $1.23
- Resistance Level
- GPRK $6.76
- CERS $1.42
- Average True Range (ATR)
- GPRK 0.47
- CERS 0.11
- MACD
- GPRK 0.01
- CERS 0.01
- Stochastic Oscillator
- GPRK 36.36
- CERS 80.65
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil and Argentina. The company generates revenue from the sale of crude oil, condensate and natural gas net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.